Answers are grounded in this paper and cite their sources.
Breast cancer therapies that induce iatrogenic menopause expose premenopausal women to abrupt estrogen deprivation and frequently result in genitourinary syndrome of menopause (GSM), yet the timing and durability of symptom onset and associated changes in vaginal health and ecology remain poorly understood. In this multicentre prospective longitudinal study, 60 premenopausal women with stage I–IIIC breast cancer were followed from before treatment initiation through iatrogenic menopause across four study visits. At each visit, vulvovaginal health, GSM manifestations, vaginal microbiome composition, menopausal status, and general and sexual wellbeing were assessed using gynecologic examination, 16S rRNA amplicon sequencing, serum estradiol measurements and validated questionnaires. Within three months of menopause onset, participants exhibited significant deterioration in vulvovaginal health and an increased prevalence of sexual dysfunction, particularly among those receiving endocrine therapy. Menopause onset was accompanied by a rapid loss of Lactobacillus dominance and an increase in vaginal microbial diversity, with more pronounced changes in endocrine therapy recipients. These microbial shifts persisted for up to 33 months, including among patients who later regained premenopausal estrogen levels, suggesting limited resilience of the vaginal ecosystem. Our findings provide robust longitudinal evidence that iatrogenic menopause rapidly and durably disrupts vaginal health and microbial ecology, underscoring the need for early intervention and supporting the exploration of microbiome-modulating strategies to support survivorship care.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: